SCHEMBL30212469

SCHEMBL30212469

CC(C)(C)OC(=O)NC1CC(Oc2ccc(C(C)(C)c3ccc(Oc4ccnc(Cl)c4)cc3)cc2)C1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BTK Q06187 4/20 0.38
EPHX2 P34913 2/20 0.38
RAF1 P04049 1/20 0.38
PIK3CD O00329 1/20 0.38
KDM1A O60341 2/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
EIF2AK4 Q9P2K8 1/20 0.35
MAOB P27338 1/20 0.35
DGAT1 O75907 1/20 0.35
SCN9A Q15858 1/20 0.35
P2RX3 P56373 3/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
BRAF P15056 2/20 0.34
KDR P35968 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27234162 0.90 P2RX3 (0.37) EPHX2RAF1SCN9AP2RX3BRAF
SCHEMBL27234155 0.90 P2RX3 (0.37) EPHX2RAF1SCN9AP2RX3BRAF
SCHEMBL30988252 0.90 BTK (0.40) BTKEPHX2RAF1PIK3CDKDM1A
SCHEMBL24922291 0.90 BTK (0.40) BTKEPHX2RAF1PIK3CDKDM1A
SCHEMBL30988268 0.88 PIK3CD (0.40) BTKEPHX2PIK3CDKDM1AKMT2A
SCHEMBL24921088 0.86 PIK3CD (0.37) BTKEPHX2RAF1PIK3CDKDM1A
SCHEMBL24922293 0.86 PIK3CD (0.37) BTKEPHX2PIK3CDKDM1AKMT2A
SCHEMBL24921854 0.84 PIK3CD (0.41) BTKEPHX2PIK3CDKDM1AKMT2A
SCHEMBL30988333 0.84 PIK3CD (0.41) BTKEPHX2PIK3CDKDM1AKMT2A
SCHEMBL24920930 0.83 PIK3CD (0.40) BTKEPHX2PIK3CDKDM1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250051347-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER Hinova Pharmaceuticals, Inc. (CN) 2025-02-13 US disclosed
EP-4378936-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER Hinova Pharmaceuticals Inc. (CN) 2024-06-05 EP disclosed
WO-2023006097-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER 海创药业股份有限公司 2023-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051347-A1 BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND AND USE THEREOF AS ANDROGEN RECEPTOR DEGRADER AR, ADRM1, MDM2 BTK 4266/4885EPHX2 2762/4885RAF1 3226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.